We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
-17.68%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$687M
AUM Growth
+$105M
(+18%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
35.31%
Top 10 Holdings %
Top 10 Hldgs %
70.66%
Holding
51
New
13
Increased
20
Reduced
3
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$82.8M |
| 2 |
NVRO
NEVRO CORP.
NVRO
|
+$58.1M |
| 3 |
AET
Aetna Inc
AET
|
+$49.4M |
| 4 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$42.6M |
| 5 |
Amgen
AMGN
|
+$32.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$51.3M |
| 2 |
Perrigo
PRGO
|
+$36.6M |
| 3 |
Becton Dickinson
BDX
|
+$20.8M |
| 4 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$17.1M |
| 5 |
Medtronic
MDT
|
+$16.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.9% |
| 2 | Financials | 7.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ACHN
26
DELISTED
Achillion Pharmaceuticals
ACHN
| $4.28M | 0.62% |
619,000
-257,000
| -29% | -$2.09M |
|
27
MiMedx Group
MDXG
$630M
| $4.02M | 0.58% |
416,361
-664,198
| -61% | -$7.01M |
|
|
VXRT
28
DELISTED
Vaxart
VXRT
| $3.44M | 0.5% |
157,855
+10,810
| +7% | +$262K |
|
29
Rigel Pharmaceuticals
RIGL
$723M
| $3.4M | 0.49% |
137,559
+19,910
| +17% | +$594K |
|
|
ARNA
30
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $3.37M | 0.49% |
+176,699
| New | +$6M |
|
|
ADYX
31
DELISTED
Adynxx Inc
ADYX
| $2.92M | 0.43% |
15,361
+1,701
| +12% | +$476K |
|
32
Standard BioTools
LAB
$342M
| $2.52M | 0.37% |
+310,587
| New | +$4.89M |
|
|
SIEN
33
DELISTED
Sientra, Inc.
SIEN
| $2.48M | 0.36% |
+24,429
| New | +$5.54M |
|
|
XOMA
34
DELISTED
Xoma
XOMA
| $1.75M | 0.25% |
+116,355
| New | +$3.67M |
|
|
NDRM
35
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $1.16M | 0.17% |
+56,000
| New | +$1.15M |
|
|
ZGNX
36
DELISTED
Zogenix, Inc.
ZGNX
| $963K | 0.14% |
+71,300
| New | +$1.29M |
|
|
37
Becton Dickinson
BDX
$46.4B
| – | – |
-150,573
| Closed | -$20.8M |
|
|
ESPR
38
DELISTED
Esperion Therapeutics
ESPR
| – | – |
-153,900
| Closed | -$12.6M |
|
39
Johnson & Johnson
JNJ
$640B
| – | – |
-171,400
| Closed | -$16.7M |
|
|
40
Labcorp
LH
$25.2B
| – | – |
-492,256
| Closed | -$51.3M |
|
|
41
Medtronic
MDT
$112B
| – | – |
-228,400
| Closed | -$16.9M |
|
|
42
Perrigo
PRGO
$1.44B
| – | – |
-198,100
| Closed | -$36.6M |
|
43
Talphera
TLPH
$68M
| – | – |
-39,919
| Closed | -$3.38M |
|
|
XENT
44
DELISTED
Intersect ENT, Inc
XENT
| – | – |
-233,757
| Closed | -$6.69M |
|
|
ESRX
45
DELISTED
Express Scripts Holding Company
ESRX
| – | – |
-93,300
| Closed | -$8.3M |
|
|
KND
46
DELISTED
Kindred Healthcare
KND
| – | – |
-576,876
| Closed | -$11.7M |
|
|
AGN.PRA
47
DELISTED
Allergan plc
AGN.PRA
| – | – |
-4,900
| Closed | -$5.12M |
|
|
PMC
48
DELISTED
PharMerica Corporation
PMC
| – | – |
-229,214
| Closed | -$7.63M |
|
|
SGNT
49
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
| – | – |
-453,392
| Closed | -$11M |
|
|
DYAX
50
DELISTED
DYAX CORPORATION
DYAX
| – | – |
-440,433
| Closed | -$11.7M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q3 2015 Portfolio in Review
As of Q3 2015, Senzar Asset Management held 51 positions worth $687M, up 18% from $582M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Senzar Asset Management deployed $243M of net new capital in Q3 2015, opening 13 new positions and adding to 20 existing holdings. Its largest new stake was MALLINCKRODT PUBLIC LIMITED COMPANY: 430,200 shares worth $27.5M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Orthofix Medical, an estimated $8.01M trimmed.
- Senzar Asset Management's largest Q3 2015 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 430,200 shares worth $27.5M.
- Senzar Asset Management added most to Viatris in Q3 2015, an estimated $82.8M increase.
- Senzar Asset Management's biggest Q3 2015 reduction was Orthofix Medical, cutting an estimated $8.01M.
- Senzar Asset Management fully exited Labcorp in Q3 2015, selling an estimated $51.3M.
- Senzar Asset Management's ten largest holdings make up 71% of its $687M portfolio in Q3 2015.
- Senzar Asset Management opened 13 new positions and closed 15 in Q3 2015.
- Senzar Asset Management's portfolio value rose 18% quarter-over-quarter to $687M.
Based on Senzar Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.